Beigene Ltd (NASDAQ:BGNE) CEO John Oyler sold 31,989 shares of the firm’s stock in a transaction on Monday, March 20th. The stock was sold at an average price of $39.39, for a total transaction of $1,260,046.71. Following the completion of the sale, the chief executive officer now owns 197,640 shares in the company, valued at approximately $7,785,039.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

John Oyler also recently made the following trade(s):

  • On Monday, March 6th, John Oyler sold 108,999 shares of Beigene stock. The stock was sold at an average price of $40.91, for a total transaction of $4,459,149.09.
  • On Tuesday, February 21st, John Oyler sold 64,963 shares of Beigene stock. The stock was sold at an average price of $40.55, for a total transaction of $2,634,249.65.

Shares of Beigene Ltd (NASDAQ:BGNE) traded up 0.03% during midday trading on Monday, hitting $39.56. 95,629 shares of the stock traded hands. Beigene Ltd has a 12-month low of $24.53 and a 12-month high of $41.89. The company’s market capitalization is $1.30 billion. The firm’s 50 day moving average price is $38.21 and its 200 day moving average price is $33.14.

Insider Buying and Selling by Quarter for Beigene (NASDAQ:BGNE)

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/20/john-oyler-sells-31989-shares-of-beigene-ltd-bgne-stock.html

Your IP Address:

A number of institutional investors have recently added to or reduced their stakes in BGNE. Baillie Gifford & Co. increased its position in Beigene by 0.7% in the fourth quarter. Baillie Gifford & Co. now owns 69,284 shares of the company’s stock worth $2,103,000 after buying an additional 449 shares during the period. State Street Corp increased its position in Beigene by 6.0% in the fourth quarter. State Street Corp now owns 33,769 shares of the company’s stock worth $1,025,000 after buying an additional 1,917 shares during the period. Vident Investment Advisory LLC increased its position in Beigene by 9.7% in the fourth quarter. Vident Investment Advisory LLC now owns 24,958 shares of the company’s stock worth $758,000 after buying an additional 2,207 shares during the period. Susquehanna International Group LLP purchased a new position in Beigene during the third quarter worth $455,000. Finally, Norges Bank purchased a new position in Beigene during the fourth quarter worth $607,000. 33.01% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts have recently issued reports on the stock. Maxim Group set a $52.00 price objective on shares of Beigene and gave the stock a “buy” rating in a research note on Thursday, March 2nd. Zacks Investment Research downgraded shares of Beigene from a “buy” rating to a “hold” rating in a research note on Tuesday, January 17th.

Beigene Company Profile

BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.

5 Day Chart for NASDAQ:BGNE

Receive News & Ratings for Beigene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.